Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Brief Summary: This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel in the treatment of subjects with advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Primary Outcome Measure:

• Progression free survival (PFS)

Secondary Outcome Measures:

* Object Response Rate (ORR), duration of response (DOR). CA-125 response rate
* Safety and Tolerability
* Change and duration of change on blood levels of CA-125


Options:
A: Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone
B: Arm Label: Arm I (paclitaxel, docetaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm III (gemcitabine hydrochloride, carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Arm Label: Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)
C: Arm Label: chemotherapy, avelumab and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy + avelumab followed by avelumab + talazoparib | Arm Label: chemotherapy, and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy followed by talazoparib maintenance | Arm Label: chemotherapy and bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy + bevacizumab followed by bevacizumab | Intervention Type: DRUG; Name: Chemotherapy + avelumab followed by avelumab + talazoparib; Assigned to Arm(s): chemotherapy, avelumab and talazoparib | Intervention Type: DRUG; Name: Chemotherapy followed by talazoparib maintenance; Assigned to Arm(s): chemotherapy, and talazoparib | Intervention Type: DRUG; Name: Chemotherapy + bevacizumab followed by bevacizumab; Assigned to Arm(s): chemotherapy and bevacizumab
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C

Answer: D